Based on the key measurements obtained from Laboratory's financial statements, Laboratory of may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. As of now, Laboratory's Total Stockholder Equity is increasing as compared to previous years. The Laboratory's current Property Plant And Equipment Net is estimated to increase to about 3.1 B, while Other Current Liabilities is projected to decrease to under 478.7 M. Key indicators impacting Laboratory's financial strength include:
The financial analysis of Laboratory is a critical element in measuring its lifeblood. Investors should not minimize Laboratory's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Cash And Equivalents
744.54 Million
Laboratory
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Dividends Paid
Sale Purchase Of Stock
Other Non Cash Items
Change To Inventory
Stock Based Compensation
Other Cashflows From Investing Activities
Change To Account Receivables
Change To Liabilities
Investments
Change Receivables
Net Borrowings
Total Cashflows From Investing Activities
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Netincome
Change To Operating Activities
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Long Term Debt Total
Intangible Assets
Short Term Debt
Inventory
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Common Stock
Common Stock Total Equity
Other Liab
Other Assets
Long Term Debt
Property Plant Equipment
Good Will
Treasury Stock
Short Term Investments
Current Deferred Revenue
Net Tangible Assets
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Deferred Long Term Liab
Long Term Investments
Non Current Liabilities Other
Short Long Term Debt
Capital Lease Obligations
Cash And Equivalents
Net Invested Capital
Net Working Capital
Capital Stock
Interest Expense
Total Revenue
Gross Profit
Operating Income
Ebit
Ebitda
Depreciation And Amortization
Other Operating Expenses
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Net Income Applicable To Common Shares
Minority Interest
Net Income From Continuing Ops
Non Recurring
Non Operating Income Net Other
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Laboratory Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Laboratory's financial statements are interrelated, with each one affecting the others. For example, an increase in Laboratory's assets may result in an increase in income on the income statement.
Laboratory competes with Humana, Cigna Corp, Elevance Health, Centene Corp, and UnitedHealth Group. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina. Laboratory Corp operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 75000 people.
Comparative valuation techniques use various fundamental indicators to help in determining Laboratory's current stock value. Our valuation model uses many indicators to compare Laboratory value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Laboratory competition to find correlations between indicators driving Laboratory's intrinsic value. More Info.
Laboratory of is rated below average in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers reporting about 0.73 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Laboratory of is roughly 1.37 . As of now, Laboratory's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Laboratory's earnings, one of the primary drivers of an investment's value.
Laboratory Systematic Risk
Laboratory's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Laboratory volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Laboratory correlated with the market. If Beta is less than 0 Laboratory generally moves in the opposite direction as compared to the market. If Laboratory Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Laboratory is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Laboratory is generally in the same direction as the market. If Beta > 1 Laboratory moves generally in the same direction as, but more than the movement of the benchmark.
Laboratory Thematic Clasifications
Laboratory of is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Laboratory Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Laboratory's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Laboratory growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Laboratory help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Laboratory of. We use our internally-developed statistical techniques to arrive at the intrinsic value of Laboratory of based on widely used predictive technical indicators. In general, we focus on analyzing Laboratory Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Laboratory's daily price indicators and compare them against related drivers.
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance